ArticleNature medicine2023

CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial.

Andreas Mackensen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.